HGEN Research and Charts

HGEN - Humanigen Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-03-22 (Delayed quote data 2024-07-11)

Last 0.00	Change ⇓ 0.00 (0.00%)	Volume 295,735
	Open 0.00	High 0.00	Low 0.00

8EMA (Daily) 0.00	40EMA (Daily) 0.00	50EMA (Daily) 0.00	STO (Daily) 0.000	MACD Hist (Daily) 0.000
8EMA (Weekly) 0.000	40EMA (Weekly) 0.04	50EMA (Weekly) 0.10	STO (Weekly) 0.000	MACD Hist (Weekly) 0.009


Company Profile
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.